Regeneron Pharmaceuticals Inc (REGN)
826.55
-2.32
(-0.28%)
USD |
NASDAQ |
Nov 05, 11:22
Regeneron Pharmaceuticals Cash from Operations (Quarterly): 1.291B for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.291B |
| June 30, 2024 | 354.00M |
| March 31, 2024 | 1.512B |
| December 31, 2023 | 1.090B |
| September 30, 2023 | 1.114B |
| June 30, 2023 | 1.022B |
| March 31, 2023 | 1.368B |
| December 31, 2022 | 1.720B |
| September 30, 2022 | 628.90M |
| June 30, 2022 | 564.40M |
| March 31, 2022 | 2.102B |
| December 31, 2021 | 2.372B |
| September 30, 2021 | 3.414B |
| June 30, 2021 | 626.70M |
| March 31, 2021 | 668.50M |
| December 31, 2020 | 1.231B |
| September 30, 2020 | -254.30M |
| June 30, 2020 | 943.40M |
| March 31, 2020 | 698.00M |
| December 31, 2019 | 787.40M |
| September 30, 2019 | 557.30M |
| June 30, 2019 | 188.30M |
| March 31, 2019 | 897.00M |
| December 31, 2018 | 728.80M |
| September 30, 2018 | 452.90M |
| Date | Value |
|---|---|
| June 30, 2018 | 394.60M |
| March 31, 2018 | 618.80M |
| December 31, 2017 | 566.94M |
| September 30, 2017 | 414.83M |
| June 30, 2017 | -30.57M |
| March 31, 2017 | 355.90M |
| December 31, 2016 | 390.38M |
| September 30, 2016 | 651.03M |
| June 30, 2016 | 399.50M |
| March 31, 2016 | 44.99M |
| December 31, 2015 | 281.82M |
| September 30, 2015 | 892.85M |
| June 30, 2015 | 257.83M |
| March 31, 2015 | -101.73M |
| December 31, 2014 | 198.18M |
| September 30, 2014 | 164.32M |
| June 30, 2014 | 336.41M |
| March 31, 2014 | 53.53M |
| December 31, 2013 | 281.73M |
| September 30, 2013 | 92.46M |
| June 30, 2013 | 128.16M |
| March 31, 2013 | 86.25M |
| December 31, 2012 | 93.18M |
| September 30, 2012 | -2.382M |
| June 30, 2012 | -78.38M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-254.30M
Minimum
Sep 2020
3.414B
Maximum
Sep 2021
1.163B
Average
1.056B
Median
Cash from Operations (Quarterly) Benchmarks
| Amgen Inc | 3.571B |
| Eli Lilly and Co | 3.712B |
| Pfizer Inc | -1.781B |
| Biogen Inc | 935.60M |
| Vertex Pharmaceuticals Inc | -3.754B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -574.40M |
| Cash from Financing (Quarterly) | -634.00M |
| Free Cash Flow | 3.319B |
| Free Cash Flow Per Share (Quarterly) | 9.030 |
| Free Cash Flow to Equity (Quarterly) | 1.049B |
| Free Cash Flow to Firm (Quarterly) | 1.049B |
| Free Cash Flow Yield | 3.49% |